Pascal Claudepierre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pascal Claudepierre has a total of 349 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Wendling
University Marie et Louis Pasteur, Departement of Rheumatology, University Hospital, of Besançon, Boulevard Fleming, Besançon, France
16 shared publications - Laura Pina Vegas
Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
12 shared publications - Maxime Dougados
Hopital Cochin, Rheumatology, Université Paris Descartes Faculté de Médecine, Paris, France
11 shared publications - Laure Gossec
INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Team Pepites, Paris, France
9 shared publications Philippe Goupille
Department of Rheumatology, University of Tours, UPR CNRS 4301 CBM, NMNS, University Hospital of Tours , Tours
9 shared publicationsAdeline Ruyssen-Witrand
Pierre-Paul Riquet University Hospital, Toulouse University, INSERM U1291 Department of Rheumatology Toulouse
7 shared publications
Latest Publications
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- Open Access
Influence of initial axial involvement on the phenotypic evolution of axial spondyloarthritis: 10-year data from the DESIR cohort
Objectives: To investigate whether the initial location of inflammatory axial pain in axial spondyloarthritis (axSpA) is associated with the development of peripheral or extra-rheumatological manifestations over a 10-year period. Methods: Data were drawn from the 10-year prospective DESIR (Devenir des Spondylarthropathies Indifférenciées Récentes; French Cohort of Undifferentiated Spondyloarthritis ) cohort of axSpA at disease onset. Patients with available data on the initial location of inflammatory axial pain were included. The main outcomes were the occurrence of extra-axial manifestations (arthritis, dactylitis, enthesitis) and extra-rheumatological manifestations (psoriasis, uveitis, inflammatory bowel disease). Patients were categorised according to the initial location of inflammatory axial pain as cervicothoracic, lumbosacral or diffuse (involving both regions). Associations between inflammatory axial pain location and extra-axial or extra-rheumatological manifestations were assessed using multivariate Cox models, adjusted for age, sex, exposure to conventional synthetic and biological disease-modifying antirheumatic drugs (as time-dependent covariates) and the presence of these manifestations at baseline. French Cohort of Undifferentiated Spondyloarthritis: cohort of axSpA at disease onset. Patients with available data on the initial location of inflammatory axial pain were included. The main outcomes were the occurrence of extra-axial manifestations (arthritis, dactylitis, enthesitis) and extra-rheumatological manifestations (psoriasis, uveitis, inflammatory bowel disease). Patients were categorised according to the initial location of inflammatory axial pain as cervicothoracic, lumbosacral or diffuse (involving both regions). Associations between inflammatory axial pain location and extra-axial or extra-rheumatological manifestations were assessed using multivariate Cox models, adjusted for age, sex, exposure to conventional synthetic and biological disease-modifying antirheumatic drugs (as time-dependent covariates) and the presence of these manifestations at baseline. Results: Among 662 included patients, 94 (14.2%) had cervicothoracic, 466 (70.3%) had lumbosacral and 102 (15.5%) had diffuse involvement at baseline. Patients with diffuse involvement were older, had a lower education level, a lower prevalence of prior dactylitis and higher modified Stoke Ankylosing Spondylitis Spinal Score compared with other groups. Over 10 years, diffuse involvement was independently associated with an increased risk of developing arthritis (HR 1.61; 95% CI 1.15 to 2.25) compared with lumbosacral involvement. No other significant associations were observed. Conclusion: Diffuse initial axial involvement identifies a subgroup of patients with axSpA at increased risk of developing peripheral arthritis. This finding has practical implications for clinicians in early risk stratification, patient counselling and interpretation of therapeutic trial outcomes.
Open AccessInfluence of initial axial involvement on the phenotypic evolution of axial spondyloarthritis: 10-year data from the DESIR cohort
Objectives: To investigate whether the initial location of inflammatory axial pain in axial spondyloarthritis (axSpA) is associated with the development of peripheral or extra-rheumatological manifestations over a 10-year period. Methods: Data were drawn from the 10-year prospective DESIR (Devenir des Spondylarthropathies Indifférenciées Récentes; French Cohort of Undifferentiated Spondyloarthritis ) cohort of axSpA at disease onset. Patients with available data on the initial location of inflammatory axial pain were included. The main outcomes were the occurrence of extra-axial manifestations (arthritis, dactylitis, enthesitis) and extra-rheumatological manifestations (psoriasis, uveitis, inflammatory bowel disease). Patients were categorised according to the initial location of inflammatory axial pain as cervicothoracic, lumbosacral or diffuse (involving both regions). Associations between inflammatory axial pain location and extra-axial or extra-rheumatological manifestations were assessed using multivariate Cox models, adjusted for age, sex, exposure to conventional synthetic and biological disease-modifying antirheumatic drugs (as time-dependent covariates) and the presence of these manifestations at baseline. French Cohort of Undifferentiated Spondyloarthritis: cohort of axSpA at disease onset. Patients with available data on the initial location of inflammatory axial pain were included. The main outcomes were the occurrence of extra-axial manifestations (arthritis, dactylitis, enthesitis) and extra-rheumatological manifestations (psoriasis, uveitis, inflammatory bowel disease). Patients were categorised according to the initial location of inflammatory axial pain as cervicothoracic, lumbosacral or diffuse (involving both regions). Associations between inflammatory axial pain location and extra-axial or extra-rheumatological manifestations were assessed using multivariate Cox models, adjusted for age, sex, exposure to conventional synthetic and biological disease-modifying antirheumatic drugs (as time-dependent covariates) and the presence of these manifestations at baseline. Results: Among 662 included patients, 94 (14.2%) had cervicothoracic, 466 (70.3%) had lumbosacral and 102 (15.5%) had diffuse involvement at baseline. Patients with diffuse involvement were older, had a lower education level, a lower prevalence of prior dactylitis and higher modified Stoke Ankylosing Spondylitis Spinal Score compared with other groups. Over 10 years, diffuse involvement was independently associated with an increased risk of developing arthritis (HR 1.61; 95% CI 1.15 to 2.25) compared with lumbosacral involvement. No other significant associations were observed. Conclusion: Diffuse initial axial involvement identifies a subgroup of patients with axSpA at increased risk of developing peripheral arthritis. This finding has practical implications for clinicians in early risk stratification, patient counselling and interpretation of therapeutic trial outcomes.
- 4 June 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (5) , 106083
Comment on: “The effect of alcohol consumption on clinical outcomes and structural damage in patients with axial spondyloarthritis: A systematic literature review and meta-analysis. Joint Bone Spine 2025;92(1):105794” by Gendron et al.
- 4 June 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (5) , 106083
Comment on: “The effect of alcohol consumption on clinical outcomes and structural damage in patients with axial spondyloarthritis: A systematic literature review and meta-analysis. Joint Bone Spine 2025;92(1):105794” by Gendron et al.
- 27 May 2026
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (6) , 1-10
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives
The concept of difficult-to-treat (D2T)/difficult-to-manage (DTM) disease was first defined in rheumatoid arthritis (RA). Recent definitions for axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) combine non-response to treatment including targeted and biologic treatment, inflammatory disease activity, and patient symptoms. This concept could apply to other chronic inflammatory diseases such as psoriasis (PsO) and inflammatory bowel disease (IBD). A consensus definition of D2T IBD is available but is yet to be fully articulated in PsO. This article aims to provide an expert overview of the shared elements and potential differences between the definitions and concepts of D2T/D2M in these diseases. D2T/D2M definitions should allow better evaluation of refractory diseases, accurate determination of disease severity, and effective treatment of the D2T areas or domains. Definitions should consider response to previous lines of treatment, control of inflammation, and global disease improvement, and consider the impact of D2T disease on patient status/quality of life. Proof-of-concept studies need to assess the current and future definitions of D2T/D2M populations in axSpA, PsA, PsO, and IBD, to accurately determine the prevalence of patients meeting each of those D2T criteria sets, and to identify risk factors, disease burden, and appropriate management strategies.
- 27 May 2026
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (6) , 1-10
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives
The concept of difficult-to-treat (D2T)/difficult-to-manage (DTM) disease was first defined in rheumatoid arthritis (RA). Recent definitions for axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) combine non-response to treatment including targeted and biologic treatment, inflammatory disease activity, and patient symptoms. This concept could apply to other chronic inflammatory diseases such as psoriasis (PsO) and inflammatory bowel disease (IBD). A consensus definition of D2T IBD is available but is yet to be fully articulated in PsO. This article aims to provide an expert overview of the shared elements and potential differences between the definitions and concepts of D2T/D2M in these diseases. D2T/D2M definitions should allow better evaluation of refractory diseases, accurate determination of disease severity, and effective treatment of the D2T areas or domains. Definitions should consider response to previous lines of treatment, control of inflammation, and global disease improvement, and consider the impact of D2T disease on patient status/quality of life. Proof-of-concept studies need to assess the current and future definitions of D2T/D2M populations in axSpA, PsA, PsO, and IBD, to accurately determine the prevalence of patients meeting each of those D2T criteria sets, and to identify risk factors, disease burden, and appropriate management strategies.
- 8 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas
Objectives: Ultrasound (US) is a valuable tool to detect inflammation in peripheral psoriatic arthritis (pPsA). This multicentre study assessed the intra- and inter-reader reliability of US-detected elementary lesions in peripheral psoriatic arthritis (pPsA) and evaluated the impact of standardized training on reliability, as a first step to guide multicentre assessment in the APACHE cohort. Methods: A cross-sectional study was conducted to analyse the reliability of pPsA US lesions, as a first step in an ongoing predictive cohort (APACHE, NCT03768271) study. Three web-based reliability exercises were carried out between 2020 and 2024. Inter-rater and intra-rater reliability were assessed using Light’s kappa (κ). During the third reliability exercise, a reference atlas of elementary US lesions in dactylitis was developed. Results: Experienced and trainee sonographers from 30 recruiting centres participated into the study. In step 1, intra-reader kappas were moderate-to-good for synovitis (0.50–0.80), tenosynovitis (0.51–0.63), enthesitis (0.62–0.73), and poor for dactylitis (0.31–0.47); inter-reader kappas were lower for synovitis (0.32–0.70), tenosynovitis (0.40–0.49), enthesitis (0.47–0.60) and dactylitis (0.13–0.24). In Step 2, reliability improved notably in expert and trainees except for dactylitis [intra-reader: synovitis (0.81–0.90), tenosynovitis (0.66–0.83), enthesitis (0.61–0.81), dactylitis (0.37–0.47); inter-reader: synovitis c(0.72–0.84), tenosynovitis (0.55–0.76), enthesitis (0.37–0.59), dactylitis (0.12–0.30)]. Step 3 achieved moderate-to-good reliability for dactylitis (intra 0.69–0.80, inter 0.46–0.68). An atlas was produced based on expert consensus and lesion identification rates among sonographers. Conclusion: Standardized training was associated with a marked improvement in intra- and inter-reader reliability for the assessment of elementary pPsA lesions. The consensus-based US atlas provides practical guidance for identifying challenging dactylitis-related lesions in clinical and research settings.
- 8 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas
Objectives: Ultrasound (US) is a valuable tool to detect inflammation in peripheral psoriatic arthritis (pPsA). This multicentre study assessed the intra- and inter-reader reliability of US-detected elementary lesions in peripheral psoriatic arthritis (pPsA) and evaluated the impact of standardized training on reliability, as a first step to guide multicentre assessment in the APACHE cohort. Methods: A cross-sectional study was conducted to analyse the reliability of pPsA US lesions, as a first step in an ongoing predictive cohort (APACHE, NCT03768271) study. Three web-based reliability exercises were carried out between 2020 and 2024. Inter-rater and intra-rater reliability were assessed using Light’s kappa (κ). During the third reliability exercise, a reference atlas of elementary US lesions in dactylitis was developed. Results: Experienced and trainee sonographers from 30 recruiting centres participated into the study. In step 1, intra-reader kappas were moderate-to-good for synovitis (0.50–0.80), tenosynovitis (0.51–0.63), enthesitis (0.62–0.73), and poor for dactylitis (0.31–0.47); inter-reader kappas were lower for synovitis (0.32–0.70), tenosynovitis (0.40–0.49), enthesitis (0.47–0.60) and dactylitis (0.13–0.24). In Step 2, reliability improved notably in expert and trainees except for dactylitis [intra-reader: synovitis (0.81–0.90), tenosynovitis (0.66–0.83), enthesitis (0.61–0.81), dactylitis (0.37–0.47); inter-reader: synovitis c(0.72–0.84), tenosynovitis (0.55–0.76), enthesitis (0.37–0.59), dactylitis (0.12–0.30)]. Step 3 achieved moderate-to-good reliability for dactylitis (intra 0.69–0.80, inter 0.46–0.68). An atlas was produced based on expert consensus and lesion identification rates among sonographers. Conclusion: Standardized training was associated with a marked improvement in intra- and inter-reader reliability for the assessment of elementary pPsA lesions. The consensus-based US atlas provides practical guidance for identifying challenging dactylitis-related lesions in clinical and research settings.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Relationship between spinal lesions related to axial spondyloarthritis and degenerative spinal lesions: 10-year follow-up of the DESIR cohort
Objective: This study aimed to investigate the relationship between spinal axial spondyloarthritis (axSpA)-related lesions and degenerative lesions (DLs) over 10 years (10Y). Methods: Whole spine MRI and cervical/lumbar spine radiographs at baseline/5Y/10Y from patients with axSpA from the DESIR cohort were assessed for axSpA-related lesions and DLs by three independent readers, different teams for the two lesion types. We used multilevel (patient and vertebra, considering consensus across readers), standard and time-lagged autoregressive generalized estimating equation (GEE) models. The relationship between syndesmophytes and the subsequent development of osteophytes/syndesmophytes in adjacent vertebrae on radiographs was analysed using a time-lagged autoregressive GEE model, after excluding vertebrae with both lesions. All models were adjusted for age, sex, HLA-B27 status, BMI, smoking and job type, and bDMARDs during follow-up. Results: Data from 326 patients (35 [S.D. = 9] years; 46% men) showed a significant association between axSpA-related lesions on MRI and the total number of DLs on MRI, though the effect sizes were small (β-coefficients: 0.07–0.17). On radiographs, paravertebral syndesmophytes were significantly associated with the total number of DLs (β-coefficient: 0.37; 95%CI: 0.26–0.48). However, these associations were not found in time-lagged autoregressive models. Syndesmophytes increased the risk of adjacent syndesmophyte [odds ratio (OR):6.92; 95%CI: 2.44–19.61], but not of osteophytes (OR: 1.05; 95%CI: 0.25–4.36). Conclusion: Although significant associations were found between axSpA-related lesions and DLs at the same time point, no temporal relationship was observed. On radiographs, syndesmophytes increased the risk of syndesmophytes at adjacent levels, but there was no association with osteophyte development. AxSpA-related lesions and DLs coexist, but progress independently of each other.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Relationship between spinal lesions related to axial spondyloarthritis and degenerative spinal lesions: 10-year follow-up of the DESIR cohort
Objective: This study aimed to investigate the relationship between spinal axial spondyloarthritis (axSpA)-related lesions and degenerative lesions (DLs) over 10 years (10Y). Methods: Whole spine MRI and cervical/lumbar spine radiographs at baseline/5Y/10Y from patients with axSpA from the DESIR cohort were assessed for axSpA-related lesions and DLs by three independent readers, different teams for the two lesion types. We used multilevel (patient and vertebra, considering consensus across readers), standard and time-lagged autoregressive generalized estimating equation (GEE) models. The relationship between syndesmophytes and the subsequent development of osteophytes/syndesmophytes in adjacent vertebrae on radiographs was analysed using a time-lagged autoregressive GEE model, after excluding vertebrae with both lesions. All models were adjusted for age, sex, HLA-B27 status, BMI, smoking and job type, and bDMARDs during follow-up. Results: Data from 326 patients (35 [S.D. = 9] years; 46% men) showed a significant association between axSpA-related lesions on MRI and the total number of DLs on MRI, though the effect sizes were small (β-coefficients: 0.07–0.17). On radiographs, paravertebral syndesmophytes were significantly associated with the total number of DLs (β-coefficient: 0.37; 95%CI: 0.26–0.48). However, these associations were not found in time-lagged autoregressive models. Syndesmophytes increased the risk of adjacent syndesmophyte [odds ratio (OR):6.92; 95%CI: 2.44–19.61], but not of osteophytes (OR: 1.05; 95%CI: 0.25–4.36). Conclusion: Although significant associations were found between axSpA-related lesions and DLs at the same time point, no temporal relationship was observed. On radiographs, syndesmophytes increased the risk of syndesmophytes at adjacent levels, but there was no association with osteophyte development. AxSpA-related lesions and DLs coexist, but progress independently of each other.
- Open Access
- 27 May 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (6) , 105930
Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort
- 27 May 2025
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (6) , 105930
Open AccessEarly peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort
- Open Access
Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)
Objectives: To assess the potential impact of targeted therapies for psoriatic arthritis (PsA) on symptomatic treatments (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics), methotrexate and mood disorder treatments and on hospitalisation and sick leave. Methods: Using the French health insurance database, this nationwide cohort study included adults with PsA who were new users (not in the year before the index date) of targeted therapies for ≥9 months during 2015–2021. Main endpoints were difference in proportion of users of associated treatments, hospitalisations and sick leaves between 3 and 9 months after and 6 months before targeted therapy initiation. Logistic regression models adjusted for sex, age, psoriasis, inflammatory bowel disease and Charlson Comorbidity Index compared the impact of biologics initiation (tumour necrosis factor inhibitor (TNFi)/interleukin 17 inhibitor (IL17i)/IL12/23i) on associated treatment discontinuation. Results: Among 9793 patients initiating targeted therapy for PsA (mean age: 51±13 years, 47% men), 62% initiated TNFi, 14% IL17i, 10% IL12/23i, 1% Janus kinase inhibitor, 12% phosphodiesterase-4 inhibitor. After treatment initiation, the proportion of treatment users was significantly reduced for NSAIDs (−15%), opioid analgesics (−9%), prednisone (−9%), methotrexate (−15%) and mood disorder treatments (−2%), along with decreased hospitalisations (−12%) and sick leaves (−4%). TNFi had a greater sparing effect on NSAIDs and prednisone use than IL17i (ORa=1.04, 95% CI=1.01 to 1.07; 1.04, 1.02 to 1.06) and IL12/23i (1.07, 1.04 to 1.10; 1.06, 1.04 to 1.09). Odds of methotrexate discontinuation was reduced with TNFi versus IL17i (0.96, 0.94 to 0.98) and IL12/23i (0.94, 0.92 to 0.97). Conclusions: Targeted therapy initiation for PsA reduced the use of associated treatment and healthcare, with TNFi having a slightly greater effect than IL17i and IL12/23i, except for methotrexate discontinuation.
Open AccessImpact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)
Objectives: To assess the potential impact of targeted therapies for psoriatic arthritis (PsA) on symptomatic treatments (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics), methotrexate and mood disorder treatments and on hospitalisation and sick leave. Methods: Using the French health insurance database, this nationwide cohort study included adults with PsA who were new users (not in the year before the index date) of targeted therapies for ≥9 months during 2015–2021. Main endpoints were difference in proportion of users of associated treatments, hospitalisations and sick leaves between 3 and 9 months after and 6 months before targeted therapy initiation. Logistic regression models adjusted for sex, age, psoriasis, inflammatory bowel disease and Charlson Comorbidity Index compared the impact of biologics initiation (tumour necrosis factor inhibitor (TNFi)/interleukin 17 inhibitor (IL17i)/IL12/23i) on associated treatment discontinuation. Results: Among 9793 patients initiating targeted therapy for PsA (mean age: 51±13 years, 47% men), 62% initiated TNFi, 14% IL17i, 10% IL12/23i, 1% Janus kinase inhibitor, 12% phosphodiesterase-4 inhibitor. After treatment initiation, the proportion of treatment users was significantly reduced for NSAIDs (−15%), opioid analgesics (−9%), prednisone (−9%), methotrexate (−15%) and mood disorder treatments (−2%), along with decreased hospitalisations (−12%) and sick leaves (−4%). TNFi had a greater sparing effect on NSAIDs and prednisone use than IL17i (ORa=1.04, 95% CI=1.01 to 1.07; 1.04, 1.02 to 1.06) and IL12/23i (1.07, 1.04 to 1.10; 1.06, 1.04 to 1.09). Odds of methotrexate discontinuation was reduced with TNFi versus IL17i (0.96, 0.94 to 0.98) and IL12/23i (0.94, 0.92 to 0.97). Conclusions: Targeted therapy initiation for PsA reduced the use of associated treatment and healthcare, with TNFi having a slightly greater effect than IL17i and IL12/23i, except for methotrexate discontinuation.
- Open Access
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort
Background Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the disease. Thus, identifying the features that will be associated with a confirmed diagnosis over time is key. Objectives To assess the frequency and the predisposing factors for a change of an initial diagnosis in an inception axSpA cohort. Methods DESIR is an ongoing national multicentre inception axSpA cohort with currently 12.5 years of follow-up. At the entry visit and confirmed at each visit, the diagnosis of axSpA was based on the opinion of the treating rheumatologist. Follow-up was interrupted in case of a change in this initial diagnosis. Multiple imputation was used to estimate the probability of a change in the initial diagnosis of axSpA for each patient lost to follow-up. Factors predisposing to an unchanged diagnosis of axSpA were then assessed using a multivariate logistic regression model on the imputed data sets. Results Of the 708 patients included, over 10 years of follow-up, 45 (6.4%) were excluded due to a diagnosis change and 300 (42.4%) patients were lost to follow-up. Based on the imputation of these 300 patients, a change in their initial axSpA diagnosis was estimated in 42 (14.0%). Factors predisposing to an unchanged initial axSpA diagnosis during follow-up were (ORs (95% CIs)): radiographic sacroiliitis: 17.0 (4.1 to 71.0); psoriasis: 5.3 (2.0 to 14.3); CRP≥6 mg/L: 2.7 (1.3 to 5.3); good NSAID response: 2.5 (1.5 to 4.2); HLA B27+: 2.0 (1.3 to 3.3); anterior chest wall pain: 2.0 (1.2 to 3.3) and female sex: 1.9 (1.2 to 3.0). Conclusion These data suggest that a change in diagnosis in recent onset axSpA exists, but is not frequent, and is less likely to occur in the presence of objective features at baseline.
Open AccessDiagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort
Background Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the disease. Thus, identifying the features that will be associated with a confirmed diagnosis over time is key. Objectives To assess the frequency and the predisposing factors for a change of an initial diagnosis in an inception axSpA cohort. Methods DESIR is an ongoing national multicentre inception axSpA cohort with currently 12.5 years of follow-up. At the entry visit and confirmed at each visit, the diagnosis of axSpA was based on the opinion of the treating rheumatologist. Follow-up was interrupted in case of a change in this initial diagnosis. Multiple imputation was used to estimate the probability of a change in the initial diagnosis of axSpA for each patient lost to follow-up. Factors predisposing to an unchanged diagnosis of axSpA were then assessed using a multivariate logistic regression model on the imputed data sets. Results Of the 708 patients included, over 10 years of follow-up, 45 (6.4%) were excluded due to a diagnosis change and 300 (42.4%) patients were lost to follow-up. Based on the imputation of these 300 patients, a change in their initial axSpA diagnosis was estimated in 42 (14.0%). Factors predisposing to an unchanged initial axSpA diagnosis during follow-up were (ORs (95% CIs)): radiographic sacroiliitis: 17.0 (4.1 to 71.0); psoriasis: 5.3 (2.0 to 14.3); CRP≥6 mg/L: 2.7 (1.3 to 5.3); good NSAID response: 2.5 (1.5 to 4.2); HLA B27+: 2.0 (1.3 to 3.3); anterior chest wall pain: 2.0 (1.2 to 3.3) and female sex: 1.9 (1.2 to 3.0). Conclusion These data suggest that a change in diagnosis in recent onset axSpA exists, but is not frequent, and is less likely to occur in the presence of objective features at baseline.